ROAD - ROAD

Construction Partners Bolsa (NASDAQ: ROAD)

Últimas noticias sobre Construction Partners (NASDAQ:ROAD) Bolsa

Construction Partners

Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.

Stock Whisper Index

Short Sellers

Exclusives

Trading Ideas

CWST

ROAD

Explora las acciones emergentes que podrían dispararse pronto según el análisis del Índice Stock Whisper de Benzinga.

Índice Stock Whisper de Benzinga revela 5 acciones con potencial de crecimiento antes de reportes

Construction Partners, Inc. - Common Stock

Construction Partners Inc

ROAD KING INFRS UNSP/ADR by Road King Infrastructure Ltd.

ROAD MARSHALL INC by Road Marshall Inc

ROAD INFRASTRUCTURE by Road King Infrastructure Ltd.

Road King Infrastructure Ltd

ROADRUNNER TRANS SYS INC by Roadrunner Transportation Systems, Inc.

Roadrunner Transportation Systems Inc

Roadside Real Estate PLC

Roadzen Inc

Bitcoin (<a href="https://www.benzinga.com/quote/BTC-USD">BTC</a>) might not be digital gold due to its risky nature. But as an investment over the last 12 months, it's up 49% while the SPDR Gold Trust (<a href="https://www.benzinga.com/quote/GLD">GLD</a>) ETF is up 43%. Nasdaq is up around 8%. Looked at in that time frame, BTC is as good as gold, for real.
"While bitcoin continues to function as an ultra risk-on asset, paradoxically, the digital gold narrative has continued to gather strength," said Greg Waisman, Chief Operating Officer at Mercuryo, a fintech company headquartered in Canada.&nbsp;
"Bitcoin has displayed relative resilience against tariff concerns and a potential recession," he said, noting that BTC has outperformed tech stocks all year. "That might make Bitcoin seen by some as displaying characteristics more akin to a store of value such as gold," Waisman said.
The notion that Bitcoin was "as good as gold" began around 2021. Michael Novogratz, founding CEO of Galaxy Digital Holdings (<a href="https://www.benzinga.com/quote/BRPHF">BRPHF</a>), a crypto investment firm that trades on the Toronto Stock Exchange, <a href="https://www.goldmansachs.com/pdfs/insights/pages/crypto-a-new-asset-class-f/report.pdf?utm">said</a> at the time that "Bitcoin is a really convenient way to store value. The main reason everyone got into bitcoin is the same reason they got into gold—the current macro backdrop is tailor-made for it."
Novogratz later called it <a href="https://www.goldmansachs.com/insights/articles/from_briefings_18-feb-2021?utm">"digital gold"</a> during a Goldman Sachs event that same year. That theme has stuck around ever since.&nbsp;
"The digital gold label reflects Bitcoin's core proposition: scarcity, decentralization, and its role as a store of value," said Mithil Thakore, Co-Founder &amp; CEO at <a href="https://www.benzinga.com/quote/VELAR-USD">Velar</a>, a Dubai-based DeFi play.
If Bitcoin is to be likened as digital gold for its store of value, then it must be seen as the more rambunctious cousin to the yellow metal. Looked at over the last year and Bitcoin looks exactly like gold when compared to GLD. Looked at over five years and Bitcoin is a runaway train, far outpacing everything in the market, with the possible exception of Nvidia (<a href="https://www.benzinga.com/quote/NVDA">NVDA</a>) stocks. Over the last three months, Bitcoin is down 10.7%, but that's better than the Nasdaq. And it has also held its value more than Nvidia.
Gold Safer Bitcoin Since Trump, But Bitcoin Safer Bet Than The S&amp;P 500
Despite Bitcoin being beaten by gold during the recent volatility, it's done better than the S&amp;P 500. Investors lost more money holding the SPDR S&amp;P 500 (<a href="https://www.benzinga.com/quote/SPY">SPY</a>) than they lost in BTC.
In official circles, of course, Bitcoin is not digital gold. The Securities and Exchange Commission <a href="https://www.sec.gov/comments/sr-cboebzx-2021-019/srcboebzx2021019-8857582-239811.pdf?utm">makes it clear</a> to investors: don't get your wires crossed on this trade.&nbsp;
Unlike gold, Bitcoin is not a collateral currency. Central banks hold gold because it can be a ready source of foreign exchange, especially for dollars. Gold can also serve as a collateral to access dollars during a crisis. That's why gold has value because of its repeated historical pattern acting as insurance to access liquidity during times of extreme crisis. As of now, Bitcoin has yet to demonstrate the role as a collateral currency, let alone for central banks.
Earlier this month, Peter Schiff panned the idea of Bitcoin as a safe haven investment. He was mostly criticizing the Trump administration's plan to consider holding BTC in a strategic reserve fund.
"I mean, if it's digital gold, it should have something in common with gold. It should trade similarly to Gold. It should have some kind of positive correlation. It doesn't have any," Schiff <a href="https://www.benzinga.com/25/04/44580634/bitcoin-is-digital-risk-not-digital-gold-asserts-peter-schiff">said</a> during his YouTube podcast. He called it the "anti-gold."&nbsp;
"Bitcoin is more than just a passive hedge," said Thakore. "Unlike gold, which sits in vaults, Bitcoin is programmable and forms the backbone of a new financial system." At Velar, Thakore said he is saying a shift from passive holding of Bitcoin in digital wallets, to active utility as a currency.&nbsp;
"Yes, Bitcoin is way more volatile than gold will ever be, but that volatility also reflects its growth phase," Thakore said. Gold has been around for thousands of years.&nbsp; Bitcoin was created in 2009. "We're witnessing the monetization of the number one digital asset in real time," he said.&nbsp; "In that sense, Bitcoin is gold with a built-in accelerator."
Disclosure: The writer of this article is a Bitcoin investor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Commodities

Opinion

Bitcoin Might Not Be As Good As Gold Yet, But This Year, It Sure Is Acting Like It

Cellectis (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN&#xAE;-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans.

News

CLLS

Cellectis Presents Research Data On TALEN And TALEB Technologies For Gene And Cellular Therapies At ASGCT Annual Meeting

Fractyl Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) ("the Company"), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced that it will deliver an oral presentation of compelling preclinical data from its Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana.
Oral Presentation Details:
Title: Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine Model Session: AAV Preclinical and Proof-of-Concept Studies Date and Time: Saturday, May 17, 2025, 9:15 a.m. – 9:30 a.m. CT Location: NOLA Theater A
The presentation will be available via the <a href="https://www.globenewswire.com/Tracker?data=aacUCQgF_Oqe0d8e_y3hmsG1Yc1wJ8J7vtDGrOFywijpE8bvkVPkvuBFk2XlW5vg7tSmk1RCOaeYE2GPEfH0QP9VxkDuoOvEvNpyCBVlpXesQo6kwqP-UmcEIaAmBw0khOcq05KG28BH3sebErxYrKb8bPbMDb5NILxzEUHB5dc=">Presentations &amp; Publications</a> section of the Fractyl website once it concludes on May 17, 2025. &nbsp;

Biotech

General

GUTS

Fractyl Health Announces It Will Present Preclinical Data From Its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform At American Society Of Gene And Cell Therapy 2025 Annual Meeting May 13-17, 2025, In New Orleans, Louisiana.

Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) released its first-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/04/b45051710/beyond-inc-delivers-significant-financial-improvement-across-key-operational-guideposts-signals-im">details from the report.&nbsp;</a>
The Details:&nbsp;Beyond reported quarterly losses of&nbsp;42 cents per share, which beat the analyst consensus estimate of&nbsp;losses of 54 cents. Quarterly revenue came in at $231.75 million,&nbsp;which missed the analyst consensus estimate of&nbsp;$288.15 million&nbsp;and is a&nbsp;decrease from revenue of&nbsp;$382.28 million&nbsp;from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, Beyond reported: 
<ul>
<li>Gross profit of $58 million, or 25.1% of net revenue, a 560 bps improvement year-over-year. </li>
<li>Sales &amp; Marketing expense of $31 million, or 13.5% of net revenue, a 430 bps improvement year-over-year. </li>
<li>Technology and G&amp;A expense of $41 million vs $50 million in 2024, a $9 million improvement year-over-year. </li>
</ul>
&#8220;While the previously disclosed decision to eliminate non-contributory SKUs and vendors led to lower revenue, we are steadfast in building a more stable foundation for profitability and growth. The sequential improvements we&#8217;ve seen —particularly in gross margin expansion and fixed cost reductions — underscore the intensity I expect in restoring the financial discipline critical to building a profitable growing business,&#8221; said Adrianne Lee, CFO of Beyond.
Outlook:&nbsp;The company said it believes it is 60 days out from transitioning from restructuring to revenue growth. 
BYON Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Beyond stock was up 22.01% after-hours at $5.03 at publication on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

After-Hours Center

Movers

Tech

BYON

Beyond Stock Rallies After Q1 EPS Beat Estimates: Details

Events

SGMO

Sangamo Therapeutics To Present At 28th Annual Meeting of the American Society of Gene & Cell Therapy May 13-17

ORIC

ORIC® Pharmaceuticals Presents Poster At AACR Highlighting Data On ORIC-944

SAIH

Saiheat FY EPS $(3.4582) Up From $(3.7916) YoY, Sales $5.54M Down From $6.78M YoY

Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) reported quarterly earnings of $4.84 per share which beat the analyst consensus estimate of $4.35 by 11.26 percent. This is a 30.81 percent increase over earnings of $3.70 per share from the same period last year. The company reported quarterly sales of $4.10 billion which missed the analyst consensus estimate of $4.15 billion by 1.31 percent. This is a 6.63 percent increase over sales of $3.85 billion the same period last year.

Earnings Beats

Earnings Misses

Universal Health Servs Q1 Adj. EPS $4.84 Beats $4.35 Estimate, Sales $4.10B Miss $4.15B Estimate

EDIT

Editas Medicine Announces Five Abstracts At 28th Annual Meeting Of American Society Of Gene And Cell Therapy

Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression
Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented
CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three oral presentations at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy, taking place in New Orleans, LA, May 13 – 17, 2025.
Details for the oral presentations are as follows:
Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of Urea Cycle Disorders Presenter: Dan Tardiff, Ph.D. Session title: Oligonucleotide Therapeutics II Session date and time: Friday May 16, 2025, 3:45 PM - 5:40 PM CT
Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of SYNGAP1-Related Disorders Presenter: Dan Tardiff, Ph.D. Session title: Oligonucleotide Therapeutics II Session date and time: May 16, 2025, 3:45 PM - 5:40 PM CT
Title: A First-in-Human Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study (SAD, MAD) in Healthy Volunteers to Evaluate the Safety and Tolerability of an Investigational Antisense Oligonucleotide Therapy (CMP-CPS-001) for the Treatment of Urea&nbsp;Cycle Diseases (UCDs): Interim Safety Readout Presenter: Yuri Maricich, M.D. Session title: Oligonucleotide Therapeutics II Session date and time: May 16, 2025, 3:45 PM - 5:40 PM CT

CAMP

CAMP4 Announces It Will Present New Preclinical Data From Its Urea Cycle Disorders And SYNGAP1-Related Disorders Programs At 28th American Society Of Gene And Cell Therapy Annual Meeting May13-17, 2025 In New Orleans, Lousiana

RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.38 by 65.79 percent. This is a 69.77 percent decrease over earnings of $0.43 per share from the same period last year.

RBB Bancorp Q1 EPS $0.13 Misses $0.38 Estimate

UFP Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPI#NASDAQ">UFPI</a>) reported quarterly earnings of $1.30 per share which missed the analyst consensus estimate of $1.57 by 17.2 percent. This is a 33.67 percent decrease over earnings of $1.96 per share from the same period last year. The company reported quarterly sales of $1.60 billion which missed the analyst consensus estimate of $1.61 billion by 0.74 percent. This is a 2.62 percent decrease over sales of $1.64 billion the same period last year.

UFPI

UFP Industries Q1 EPS $1.30 Misses $1.57 Estimate, Sales $1.60B Miss $1.61B Estimate

WIIM

CASK

Heritage Distilling Holding shares are trading higher after the company announced it regained Nasdaq compliance.

Heritage Distilling Regains Nasdaq Compliance

Universal Health Realty Q1 EPS $0.34 Down From $0.38 YoY, Sales $24.55M Down From $25.14M YoY; FFO $0.86

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 45.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 18.52% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 15.38% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 11.48% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 9.59% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 8.87% at $0.20</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 7.41% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 7.01% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 4.33% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 4.17% at $0.00</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 16.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 12.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 9.47% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 7.61% at $0.78</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 7.41% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 7.29% at $0.88</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 7.24% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 6.81% at $0.24</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 5.97% at $5.57</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 5.82% at $7.50</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 4.96% at $1.34</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 4.25% at $4.28</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 3.53% at $0.00</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BBRRF

BLGVF

BLOZF

CBDY

CLSH

CNBX

CNTMF

CRBP

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CWBHF

CXXIF

FFNTF

FUAPF

GTBIF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

MRMD

NWVCF

RMHB

SOLCF

TCNNF

YCBD

Marijuana Stock Movers For April 28, 2025

Cadence Design Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) reported first-quarter financial results Monday after the close. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/b45051800/cadence-reports-first-quarter-2025-financial-results">of the report</a>.
Q1 Earnings: Cadence Design Systems reported first-quarter revenue of $1.24 billion, in line with analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a>. Total revenue was up 23% compared to the first quarter of 2024, driven by &#8220;broad-based strength&#8221; across all of the company&#8217;s businesses.
The company reported first-quarter adjusted earnings of $1.57 per share, beating analyst estimates of $1.49 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Business highlights include semiconductor IP growth of 40% year-over-year in the first quarter and more than 50% growth in system design and analysis revenue.
Backlog totaled $6.4 billion at quarter&#8217;s end, with current remaining performance obligations of $3.2 billion. Cadence Design Systems ended the quarter with approximately $2.78 billion in cash and cash equivalents.
&#8220;Cadence delivered excellent results for the first quarter of 2025 with robust ongoing customer demand for our innovative technologies driving 23% revenue growth and 34% non-GAAP EPS growth year-over-year,&#8221; said Anirudh Devgan, president and CEO of Cadence Design Systems.
&#8220;We haven&#8217;t seen any change in customers&#8217; behavior at this time, as they continue investing in R&amp;D for their next-gen designs. Our resilient software business model, strong backlog, and AI-driven product innovations, position us well in navigating today&#8217;s dynamic macro environment.&#8221;
Guidance: Cadence Design Systems raised its full-year 2025 outlook. The company sees full-year revenue in the range of $5.15 billion to $5.23 billion, up from previous guidance of $5.14 billion to $5.22 billion. <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates currently call for full-year revenue of $5.19 billion. The company anticipates full-year adjusted earnings of $6.73 to $6.83 per share, up from prior guidance of $6.65 to $6.75 per share. Analysts are forecasting full year-earnings of $6.71 per share.
Cadence Design Systems executives will hold a conference call at 5 p.m. ET to further discuss the quarter with investors and analysts. 
CDNS Price Action: <a href="http://benzinga.com/quote/cdns" target="_blank" rel="noreferrer noopener">Cadence Design Systems shares</a> were down 1.53% after hours, trading at $281.38 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45046046/apple-q2-will-be-better-than-feared-analyst-says-iphone-company-has-proven-track-record">Apple Q2 Will Be &#8216;Better-Than-Feared&#8217;: Analyst Says iPhone Company Has &#8216;Proven Track Record&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.

Guidance

CDNS

Cadence Design Systems Q1 Earnings: Revenue In Line, EPS Beat, Raised Guidance — 'We Haven't Seen Any Change In Customers' Behavior'

Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) reported quarterly earnings of $0.24 per share which missed the analyst consensus estimate of $0.40 by 40 percent. This is a 380 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $(20.33 million) which beat the analyst consensus estimate of $(30.87 million) by 34.13 percent. This is a 51.84 percent increase over sales of $(42.22 million) the same period last year.

Two Harbors Inv Q1 Adj. EPS $0.24 Misses $0.40 Estimate, Sales $(20.33M) Beat $(30.87M) Estimate

Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) sees Q2 sales of $158.000 million-$176.000 million vs $165.75 million analyst estimate.

RMBS

Rambus Sees Q2 Licensing billings $64M - $70M, Product revenue $77M - $83M, Contract and other revenue $17M - $23M and also expects royalty revenue to be between $67 million and $73 million

Beyond shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Press Releases

Construction Partners, Inc. Completes Alabama Acquisition

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Construction Partners, Inc. - ROAD

Construction Partners, Inc. Announces Fiscal 2025 First Quarter Results

Legal

Bragar Eagel & Squire, P.C. Is Investigating Red Cat and Construction Partners and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Is Investigating Construction Partners and Skyworks and Encourages Investors to Contact the Firm

Construction Partners, Inc. to Participate in the Raymond James Institutional Investors Conference

Construction Partners, Inc. Announces Schedule for Fiscal 2025 Second Quarter Earnings Release and Conference Call

RCAT

SWKS

Arcosa

AECOM

Argan

Ameresco

APi Group

Bowman Consulting Group Ltd. - Common Stock

Bowman Consulting Group

Cadeler A/S American Depositary Share (each representing four (4) Ordinary Shares)

Comments

Construction Partners

Noticias

Últimas noticias sobre Construction Partners (NASDAQ:ROAD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL